PMID- 35386213
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2022
DP  - 2022
TI  - A Network Meta-Analysis of the Differences in Effectiveness and Safety between 
      Nivolumab and Targeted Drug Therapy in Metastatic Renal Cell Carcinoma.
PG  - 5805289
LID - 10.1155/2022/5805289 [doi]
LID - 5805289
AB  - OBJECTIVE: Nivolumab plus other drugs have provided significant benefits in 
      patients with metastatic renal cell carcinoma (mRCC), but most of the available 
      comparisons were conducted with sunitinib, and differences in efficacy with 
      targeted drugs were marginally reported. Thus, this study used a network 
      meta-analysis to compare the difference in efficacy between nivolumab combination 
      therapy and other targeted agents. METHODS: In this systematic review and network 
      meta-analysis, we searched PubMed, Embase, and Cochrane Library databases for 
      randomized controlled trials (RCTs) with the time set from database establishment 
      to December 10, 2021, using programmed death factor 1 (PD-1) inhibitors, 
      nivolumab, and sunitinib in the treatment of mRCC. Progression-free survival 
      (PFS), overall survival (OS), response rate (RR), and adverse events (AEs) were 
      collated and analyzed using the gemtc package in the R language. RESULTS: A total 
      of ten studies satisfied the inclusion criteria, including 6568 RCC cases, 10 
      drugs, and 11 treatment protocols. The Ate_Axi protocol obtained similar PFS to 
      the Niv_Cab protocol, which outperformed that of all other protocols. The Niv_Cab 
      regimen showed better PFS benefits than the Niv_Ipi regimen (HR < 1, P < 0.05), 
      and Niv_Ipi had superior PFS compared to the Ate, Eve, Paz, Sor, and Sun scheme. 
      The regimens Cab, Niv_Cab, and Niv_Ipi were associated with the best PFS 
      benefits, while Eve is the least favorable drug in terms of PFS. Niv_Cab showed 
      better OS than Ate_Bev, Eve, Paz, Sor, and Sun. The patients given Ate_Bev, Eve, 
      Paz, Sor, and Sun had inferior OS to those given Niv_Ipi. The Pem_Axi, Niv_Cab, 
      and Niv_Ipi regimens had the best OS, and that of Eve is considered least 
      promising. The Niv_Cab protocol showed significantly better RRs than the Eve, 
      Paz, Sor, and Sun protocols, and the Ate_Bev, Eve, Paz, Sor, and Sun protocols 
      presented superior RRs compared to the Niv_Ipi protocol. The Ate, Eve, and 
      Niv_Ipi regimens had the lowest incidence of AEs, and the Sor regimen had the 
      highest incidence of AEs. CONCLUSION: Among the targeted treatment options for 
      mRCC, both Niv_Cab and Niv_Ipi yield better efficacy and safety in the treatment 
      of mRCC, with Niv_Cab providing more survival benefit but with a less favorable 
      safety profile.
CI  - Copyright (c) 2022 Hongchen Qu et al.
FAU - Qu, Hongchen
AU  - Qu H
AD  - Cancer Hospital of China Medical University, Liaoning Cancer Hospital & 
      Institute, Shenyang 110042, Liaoning Province, China.
FAU - Mu, Zhongyi
AU  - Mu Z
AD  - Cancer Hospital of China Medical University, Liaoning Cancer Hospital & 
      Institute, Shenyang 110042, Liaoning Province, China.
FAU - Wang, Kai
AU  - Wang K
AD  - Cancer Hospital of China Medical University, Liaoning Cancer Hospital & 
      Institute, Shenyang 110042, Liaoning Province, China.
FAU - Hu, Bin
AU  - Hu B
AUID- ORCID: 0000-0002-3152-1402
AD  - Cancer Hospital of China Medical University, Liaoning Cancer Hospital & 
      Institute, Shenyang 110042, Liaoning Province, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220328
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC8979733
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/04/08 06:00
MHDA- 2022/04/08 06:01
PMCR- 2022/03/28
CRDT- 2022/04/07 05:09
PHST- 2022/01/13 00:00 [received]
PHST- 2022/02/14 00:00 [accepted]
PHST- 2022/04/07 05:09 [entrez]
PHST- 2022/04/08 06:00 [pubmed]
PHST- 2022/04/08 06:01 [medline]
PHST- 2022/03/28 00:00 [pmc-release]
AID - 10.1155/2022/5805289 [doi]
PST - epublish
SO  - J Oncol. 2022 Mar 28;2022:5805289. doi: 10.1155/2022/5805289. eCollection 2022.